Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

Brooklyn Health Pioneers AI-Driven Mental Health Assessment in Clinical Trials

Brooklyn Health Pioneers AI-Driven Mental Health Assessment in Clinical Trials

Brooklyn Health, a neuroscience technology startup, is revolutionizing mental health measurement and scoring in central nervous system (CNS) drug development through its innovative use of artificial intelligence. The company's platform, Willis, aims to modernize and standardize the assessment of mental health outcomes in clinical trials, addressing long-standing challenges in the field.

NoahAI News6/7/2025
Otsuka's Sibeprenlimab Shows Promise in Phase III IgAN Trial, Sparking Competition in Nephrology Market

Otsuka's Sibeprenlimab Shows Promise in Phase III IgAN Trial, Sparking Competition in Nephrology Market

Otsuka Pharmaceuticals has reported significant progress in its Phase III trial for sibeprenlimab, an investigational antibody targeting immunoglobulin A nephropathy (IgAN). The results, presented at the European Renal Association Congress, demonstrate a marked reduction in proteinuria and a favorable safety profile, potentially positioning sibeprenlimab as a leading contender in the IgAN treatment landscape.

NoahAI News6/6/2025
Corcept's Mixed Results in ALS and Ovarian Cancer Trials Highlight Potential and Challenges

Corcept's Mixed Results in ALS and Ovarian Cancer Trials Highlight Potential and Challenges

Corcept Therapeutics, a biopharmaceutical company focusing on cortisol modulation, has released results from two significant clinical trials, showcasing both promise and setbacks in their drug development pipeline. The company's efforts in amyotrophic lateral sclerosis (ALS) and platinum-resistant ovarian cancer have yielded complex outcomes, sparking discussions about the future of these treatments.

NoahAI News6/6/2025
Owens & Minor Terminates $1.36B Rotech Acquisition Amid Regulatory Hurdles

Owens & Minor Terminates $1.36B Rotech Acquisition Amid Regulatory Hurdles

Owens & Minor, a leading healthcare solutions company, has announced the termination of its planned $1.36 billion acquisition of Rotech Healthcare Holdings, a major player in the home medical equipment sector. The decision comes after both companies mutually agreed to abandon the deal due to insurmountable regulatory barriers.

NoahAI News6/6/2025
TegMine Secures Rights to OBI Pharma's ADC Technology, Advancing Glycan-Targeted Cancer Therapies

TegMine Secures Rights to OBI Pharma's ADC Technology, Advancing Glycan-Targeted Cancer Therapies

TegMine Therapeutics, a California-based biotech company led by former Stemcentrx scientists, has entered into an agreement with Taiwan's OBI Pharma to utilize their antibody-drug conjugate (ADC) technology. This strategic move aims to bolster TegMine's efforts in developing cancer treatments that target specific carbohydrate structures on tumor cells.

NoahAI News6/6/2025
Tenet Healthcare Appoints First COO as Industry Prepares for Potential Supply Chain Challenges

Tenet Healthcare Appoints First COO as Industry Prepares for Potential Supply Chain Challenges

In a significant move for one of the largest healthcare systems in the United States, Tenet Healthcare has appointed its first-ever Chief Operating Officer. This strategic decision comes as the healthcare industry braces for potential supply chain disruptions and cost increases due to evolving trade policies.

NoahAI News6/6/2025
Otsuka's Kidney Disease Drug Shows Promise in Phase 3 Study

Otsuka's Kidney Disease Drug Shows Promise in Phase 3 Study

Otsuka Pharmaceutical has released detailed data from its phase 3 trial of sibeprenlimab, a monoclonal antibody targeting immunoglobulin A (IgA) nephropathy. The results demonstrate significant improvements in kidney function markers, positioning the drug as a potential leader in an increasingly competitive market.

NoahAI News6/6/2025
Regenxbio's DMD Gene Therapy Shows Promise, But Fails to Outperform Sarepta's Elevidys

Regenxbio's DMD Gene Therapy Shows Promise, But Fails to Outperform Sarepta's Elevidys

Regenxbio has released interim results from its Phase I/II AFFINITY DUCHENNE trial for RGX-202, a gene therapy aimed at treating Duchenne muscular dystrophy (DMD). While the data demonstrates potential, analysts suggest it may not offer significant advantages over Sarepta Therapeutics' already-approved Elevidys.

NoahAI News6/6/2025
Outset Medical Appoints New CFO Amidst Leadership Transition

Outset Medical Appoints New CFO Amidst Leadership Transition

Outset Medical, a prominent manufacturer of hemodialysis systems, has announced the appointment of Renee Gaeta as its new Chief Financial Officer (CFO), effective immediately. This strategic move comes as part of a planned leadership transition aimed at positioning the company for future growth and profitability in the competitive medical device market.

NoahAI News6/6/2025
uniQure's Regulatory Progress Brings Hope for Huntington's Disease Treatment

uniQure's Regulatory Progress Brings Hope for Huntington's Disease Treatment

UniQure, a Massachusetts-based biotech company, has made significant strides in its pursuit of a groundbreaking treatment for Huntington's disease. The company recently announced alignment with the FDA on key components of its regulatory strategy for AMT-130, a one-time gene therapy that could potentially become the first disease-modifying treatment for this devastating neurodegenerative disorder.

NoahAI News6/6/2025
Lawsuit Alleges HHS Layoffs Based on Inaccurate Records, Challenging Kennedy Administration's Reorganization

Lawsuit Alleges HHS Layoffs Based on Inaccurate Records, Challenging Kennedy Administration's Reorganization

In a significant development that underscores the ongoing turmoil within the Department of Health and Human Services (HHS), seven former employees have filed a class action lawsuit against Secretary Robert F. Kennedy Jr. and other high-ranking officials. The suit, filed on Tuesday, claims that the recent mass layoffs at HHS were based on "hopelessly error-ridden" staff records, potentially violating the Privacy Act and casting a shadow over the administration's sweeping reorganization efforts.

NoahAI News6/6/2025
PBM Serve You Rx Adds Biosimilars to Formulary, Partners with Waltz Health for Specialty Pharmacy

PBM Serve You Rx Adds Biosimilars to Formulary, Partners with Waltz Health for Specialty Pharmacy

In a move set to shake up the pharmacy benefit management (PBM) landscape, alternative PBM Serve You Rx has announced the addition of two biosimilars for the popular drug Stelara to its specialty formulary. This strategic decision, coupled with a new partnership with Waltz Health, aims to generate significant savings for clients and streamline the specialty pharmacy experience for members.

NoahAI News6/6/2025
«1...545556...67»